Literature DB >> 19107347

A strategy for the use of image-guided radiotherapy (IGRT) on linear accelerators and its impact on treatment margins for prostate cancer patients.

Olaf Nairz1, Florian Merz, Heinz Deutschmann, Peter Kopp, Helmut Schöller, Franz Zehentmayr, Karl Wurstbauer, Gerhard Kametriser, Felix Sedlmayer.   

Abstract

BACKGROUND AND
PURPOSE: In external beam radiotherapy of prostate cancer, the consideration of various systematic error types leads to wide treatment margins compromising normal tissue tolerance. We investigated if systematic set-up errors can be reduced by a set of initial image-guided radiotherapy (IGRT) sessions. PATIENTS AND METHODS: 27 patients received daily IGRT resulting in a set of 882 cone-beam computed tomographies (CBCTs). After matching to bony structures, we analyzed the dimensions of remaining systematic errors from zero up to six initial IGRT sessions and aimed at a restriction of daily IGRT for 10% of all patients. For threshold definition, we determined the standard deviations (SD) of the shift corrections and selected patients out of this range for daily image guidance. To calculate total treatment margins, we demanded for a cumulative clinical target volume (CTV) coverage of at least 95% of the specified dose in 90% of all patients.
RESULTS: The gain of accuracy was largest during the first three IGRTs. In order to match precision and workload criteria, thresholds for the SD of the corrections of 3.5 mm, 2.0 mm and 4.5 mm in the left-right (L-R), cranial-caudal (C-C), and anterior-posterior (A-P) direction, respectively, were identified. Including all other error types, the total margins added to the CTV amounted to 8.6 mm in L-R, 10.4 mm in C-C, and 14.4 mm in A-P direction.
CONCLUSION: Only initially performed IGRT might be helpful for eliminating gross systematic errors especially after virtual simulation. However, even with daily IGRT performance, a substantial PTV margin reduction is only achievable by matching internal markers instead of bony anatomical structures.

Entities:  

Mesh:

Year:  2008        PMID: 19107347     DOI: 10.1007/s00066-008-1874-7

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  24 in total

1.  Performance characterization of megavoltage computed tomography imaging on a helical tomotherapy unit.

Authors:  Sanford L Meeks; Joseph F Harmon; Katja M Langen; Twyla R Willoughby; Thomas H Wagner; Patrick A Kupelian
Journal:  Med Phys       Date:  2005-08       Impact factor: 4.071

2.  IGRT with helical tomotherapy--effort and benefit in clinical routine.

Authors:  Florian Sterzing; Klaus Herfarth; Juergen Debus
Journal:  Strahlenther Onkol       Date:  2007-12       Impact factor: 3.621

3.  A grey-level image alignment algorithm for registration of portal images and digitally reconstructed radiographs.

Authors:  D H Hristov; B G Fallone
Journal:  Med Phys       Date:  1996-01       Impact factor: 4.071

4.  Positioning errors and prostate motion during conformal prostate radiotherapy using on-line isocentre set-up verification and implanted prostate markers.

Authors:  J Wu; T Haycocks; H Alasti; G Ottewell; N Middlemiss; M Abdolell; P Warde; A Toi; C Catton
Journal:  Radiother Oncol       Date:  2001-11       Impact factor: 6.280

5.  A radiographic and tomographic imaging system integrated into a medical linear accelerator for localization of bone and soft-tissue targets.

Authors:  D A Jaffray; D G Drake; M Moreau; A A Martinez; J W Wong
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-10-01       Impact factor: 7.038

6.  Independent verification of ultrasound based image-guided radiation treatment, using electronic portal imaging and implanted gold markers.

Authors:  Frank Van den Heuvel; Tanya Powell; Edward Seppi; Peter Littrupp; Mubashra Khan; Yue Wang; Jeffrey D Forman
Journal:  Med Phys       Date:  2003-11       Impact factor: 4.071

7.  Organ movements and dose exposures in teletherapy of prostate cancer using a rectal balloon.

Authors:  Hassan Elsayed; Tobias Bölling; Christos Moustakis; Stefan-Bodo Müller; Patrick Schüller; Iris Ernst; Normann Willich; Stefan Könemann
Journal:  Strahlenther Onkol       Date:  2007-11       Impact factor: 3.621

8.  A strategy to correct for intrafraction target translation in conformal prostate radiotherapy: simulation results.

Authors:  P J Keall; A D Lauve; M P Hagan; J V Siebers
Journal:  Med Phys       Date:  2007-06       Impact factor: 4.071

9.  Precision of image-guided radiotherapy (IGRT) in six degrees of freedom and limitations in clinical practice.

Authors:  Matthias Guckenberger; Juergen Meyer; Juergen Wilbert; Kurt Baier; Otto Sauer; Michael Flentje
Journal:  Strahlenther Onkol       Date:  2007-06       Impact factor: 3.621

10.  Helical tomotherapy. Experiences of the first 150 patients in Heidelberg.

Authors:  Florian Sterzing; Kai Schubert; Gabriele Sroka-Perez; Jörn Kalz; Jürgen Debus; Klaus Herfarth
Journal:  Strahlenther Onkol       Date:  2008-01       Impact factor: 3.621

View more
  24 in total

1.  Numerical deconvolution to enhance sharpness and contrast of portal images for radiotherapy patient positioning verification.

Authors:  H K Looe; Y Uphoff; D Harder; B Poppe; K C Willborn
Journal:  Strahlenther Onkol       Date:  2012-01-12       Impact factor: 3.621

2.  Clinical implementation of volumetric intensity-modulated arc therapy (VMAT) with ERGO++.

Authors:  Dirk Wolff; Florian Stieler; Brigitte Hermann; Katharina Heim; Sven Clausen; Jens Fleckenstein; Martin Polednik; Volker Steil; Frederik Wenz; Frank Lohr
Journal:  Strahlenther Onkol       Date:  2010-04-26       Impact factor: 3.621

3.  Dosimetric evaluation of high-dose-rate interstitial brachytherapy boost treatments for localized prostate cancer.

Authors:  Georgina Fröhlich; Péter Agoston; József Lövey; András Somogyi; János Fodor; Csaba Polgár; Tibor Major
Journal:  Strahlenther Onkol       Date:  2010-06-24       Impact factor: 3.621

4.  Risk factors related to interfractional variation in whole pelvic irradiation for locally advanced pelvic malignancies.

Authors:  W S Yoon; D S Yang; J A Lee; S Lee; Y J Park; C Y Kim
Journal:  Strahlenther Onkol       Date:  2012-02-10       Impact factor: 3.621

5.  Postoperative radiotherapy for advanced prostate cancer: improved local control translates into increased survival.

Authors:  Marie-Luise Sautter-Bihl; Felix Sedlmayer; Thomas Wiegel
Journal:  Strahlenther Onkol       Date:  2009-08       Impact factor: 3.621

6.  Pretreatment verification of dose calculation and delivery by means of measurements with PLEXITOM™ phantom.

Authors:  Paweł Wołowiec; Paweł Kukołowicz; Krzysztof Lis
Journal:  Rep Pract Oncol Radiother       Date:  2013-02-04

7.  Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy.

Authors:  Martin Dolezel; Karel Odrazka; Miloslava Vaculikova; Jaroslav Vanasek; Jana Sefrova; Petr Paluska; Milan Zouhar; Jan Jansa; Zuzana Macingova; Lida Jarosova; Milos Brodak; Petr Moravek; Igor Hartmann
Journal:  Strahlenther Onkol       Date:  2010-03-26       Impact factor: 3.621

8.  Three-dimensional patient setup errors at different treatment sites measured by the Tomotherapy megavoltage CT.

Authors:  S K Hui; E Lusczek; T DeFor; K Dusenbery; S Levitt
Journal:  Strahlenther Onkol       Date:  2012-03-09       Impact factor: 3.621

9.  Planning target volume margins for prostate radiotherapy using daily electronic portal imaging and implanted fiducial markers.

Authors:  David Skarsgard; Pat Cadman; Ali El-Gayed; Robert Pearcey; Patricia Tai; Nadeem Pervez; Jackson Wu
Journal:  Radiat Oncol       Date:  2010-06-10       Impact factor: 3.481

10.  A dosimetric selectivity intercomparison of HDR brachytherapy, IMRT and helical tomotherapy in prostate cancer radiotherapy.

Authors:  Johanne Hermesse; Sylvie Biver; Nicolas Jansen; Eric Lenaerts; Nathalie De Patoul; Stefaan Vynckier; Philippe Coucke; Pierre Scalliet; Philippe Nickers
Journal:  Strahlenther Onkol       Date:  2009-11-10       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.